Pending EO 12866 Regulatory Review

RIN: 0910-AI31	Received Date: 08/29/2023
Title: Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act
Agency/Subagency: HHS / FDA	Stage: Proposed Rule
Legal Deadline: None	Section 3(f)(1) Significant: No
International Impacts: No	Affordable Care Act [Pub. L. 111-148 & 111-152]: No
Pandemic Response: No	Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No